FDA sees bowel risk in early Glaxo vaccine data

WASHINGTON Wed Sep 22, 2010 9:11pm IST

Related Topics

Stocks

   

WASHINGTON (Reuters) - GlaxoSmithKline Plc's rotavirus vaccine may be linked to a small increase in a life-threatening type of bowel obstruction, U.S. health officials said on Wednesday.

Early data from a study in Mexico suggested infants given the Rotarix vaccine may face a higher chance of an intestinal problem known as intussusception in the 31 days after their first dose, the Food and Drug Administration said on its website.

"Although the results are preliminary and will require further evaluation, FDA approved revised labeling to inform healthcare providers of this finding," the agency said.

Rotavirus is the world's leading cause of severe diarrhea and dehydration in young infants. The benefits of rotavirus vaccines continue to outweigh risks, the FDA said.

Glaxo's rotavirus vaccine sales in 2009 were $440 million globally, including $118 million in the United States.

The British drug company's shares slipped 0.7 percent to $40.06 in morning trading on the New York Stock Exchange.

(Reporting by Lisa Richwine; Editing by Maureen Bavdek)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Ebola Outbreak

HEALTH SHOWCASE

H5N6 Bird Flu

H5N6 Bird Flu

China poultry farm hit in new outbreak of H5N6 bird flu.  Full Article 

Weight Loss

Weight Loss

Low-carb diets may beat low-fat options for weight loss, heart health.  Full Article 

TV and Snacking

TV and Snacking

High-action TV shows lead to more snacking: study.  Full Article 

Fighting Cyberbullies

Fighting Cyberbullies

Family dinners may help kids cope with cyberbullying.  Full Article 

Price Factor

Price Factor

Pricing is key for new heart drugs challenging cheap generics.  Full Article 

Diabetes Care

Diabetes Care

Pistachios may help reduce diabetes risk: study.  Full Article 

'Exciting' Drug

'Exciting' Drug

'Most exciting ever' Novartis drug points to huge sales.  Full Article